Frequent pathway mutations of splicing machinery in myelodysplasia

By Kenichi Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata, R. Yamamoto, Yusuke Sato, A. Sato-Otsubo, A. Kon, Masao Nagasaki and 22 more. Nature, 2011

2,072 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d0d4f29a29e99ca4a353f4e76b6dd088a4746228

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. C. López‐Otín
2. Michael R. Stratton
3. William Pao
4. Levi A. Garraway
5. P. Jänne

In Molecular Biology

1. Eric S. Lander
2. Gad Getz
3. Matthew Meyerson
4. Peter J. Campbell
5. Levi A. Garraway
6. Xose S. Puente
7. Stacey Gabriel
8. David C. Wedge

Citations in the corpus

• Lessons from the cancer genome. (2013, neutral): “genes (such as SF3A1, ZRSR2, SRSF2, and U2AF2) occurring at lower frequencies (Papaemmanuil et al., 2011; Yoshida et al., 2011).”
• Clinical and biological implications of driver mutations in myelodysplastic syndromes. (2013, background): “Indeed, mutations in genes involved in the RNA splicing machinery were mutually exclusive, as in other studies.(10,35) This implies that any one of these mutations is sufficient by itself, with no additional advantage accruing from more than 1 mutation in this pathway.”
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing (2012, background): “Identical c.101C > T, p.S34F mutations were seen in four of five U2AF1 mutant cases (Figure 3A); this is the exact mutation re- 1112 Cell 150, 1107–1120, September 14, 2012 ª2012 Elsevier Inc. ported in myelodysplastic syndrome (MDS) (Graubert et al., 2012; Yoshida et al., 2011).”